Who owns Oura Health? Ownership structure explained (2026)

Oura Health has turned a small metal ring into one of the most closely watched wearable companies in the world. Its smart ring tracks sleep, heart rate, body temperature, and activity, and has built a loyal following among health-conscious consumers, elite athletes, and medical researchers.

The company's growth trajectory has been steep. From a Finnish hardware startup with niche appeal, Oura has grown into an $11 billion business filing for a US public offering. That trajectory makes the question of who owns Oura worth understanding. Ownership shapes product direction, data governance, and the path to any future liquidity event. With a confidential IPO filing now on record with the SEC, the answers to those questions are about to become a lot more public.

This article breaks down Oura's ownership structure, traces its funding history, identifies the key people in control, and explains what the upcoming IPO means for the company.

Oura Health was founded in 2013 by Petteri Lahtela, Kari Kivelä, and Markku Koskela in Oulu, Finland. The company is incorporated in Finland, with commercial and product operations centered in San Francisco.

The core product is the Oura Ring, a titanium smart ring that tracks health metrics continuously. The device has attracted several notable user groups: NBA teams were early adopters, the ring has been worn by public figures including celebrities and heads of state, and the Finnish government purchased rings for COVID-19 research during the pandemic. Oura also sells a subscription plan that unlocks advanced health insights from the ring's data.

The company's most recent confirmed valuation is $11 billion, set during its October 2025 Series E round. CEO Tom Hale told CNBC in November 2025 that Oura could generate close to $2 billion in revenue in 2026, driven by AI investment and international expansion. The company has raised a total of approximately $2.06 billion across 12 funding rounds.

Oura Health has no public shares. Its stock does not trade on any exchange. On May 21, 2026, the company filed confidentially for a US initial public offering with the SEC. The filing has not been made public, so the terms, share structure, and offering size have not been disclosed. A public listing would significantly alter the company's ownership picture.

Because Oura is private, exact ownership percentages across founders, employees, and investors are not publicly available.

Petteri Lahtela co-founded the company and served as its first CEO. He transitioned out of the CEO role in 2022 when Tom Hale joined. Lahtela's current role and specific equity stake are not publicly disclosed.

Kari Kivelä and Markku Koskela co-founded the company alongside Lahtela. Their roles and ownership percentages are also not publicly disclosed.

Tom Hale joined as CEO in 2022 and has led the company's rapid growth phase. As a hired CEO rather than a founder, his equity stake is likely structured differently from founder ownership, though specifics are not public.

Oura has raised capital across 12 rounds, with investor composition shifting significantly in the later stages:

Note: Early-round figures and valuations are not fully disclosed across all sources. Some sources cite total funding at $1.32 billion while others report $2.06 billion, reflecting differences in what rounds are counted.

The Chernin Group (TCG) is one of the most consistently involved investors, having backed Oura from the Series B onward. TCG is a media and consumer technology investment firm led by Peter Chernin, the former Fox executive.

Forerunner Ventures is another early institutional backer, with a track record of investing in consumer-facing product companies. Dexcom, the continuous glucose monitoring company, entered as a strategic investor in 2022, signaling interest in integrating Oura's biosensing capabilities with its diabetes management ecosystem.

Fidelity Management and Research co-led the Series D and participated in the Series E, representing one of the largest financial buyers on the cap table. ICONIQ Capital, a wealth management firm known for managing assets of tech billionaires, joined in the Series E.

MSD Capital, the family office of Michael Dell, also holds a stake in Oura according to investor tracking sources.

In September 2025, Oura secured a $250 million revolving credit facility arranged by a consortium of six banks: JPMorgan, Goldman Sachs, Bank of America, Barclays, Citi, and Wells Fargo. This is a separate financing instrument from the equity rounds and provides operational liquidity without diluting existing shareholders.

In January 2026, Bloomberg reported that Oura was planning a tender offer for existing investors at roughly a 25% discount to the Series E round price. This type of transaction allows early investors to sell their shares to secondary buyers at a negotiated price, providing liquidity before the company goes public. It does not raise new capital for Oura itself.

Oura filed confidentially for a US IPO on May 21, 2026. At the current $11 billion valuation, a public listing would be one of the larger consumer tech offerings of the year. CEO Tom Hale has signaled the company is investing in artificial intelligence and international expansion as growth drivers. Specific IPO terms, share structure, and listing timeline have not been disclosed.

Tom Hale joined Oura as CEO in 2022, after the founding team brought in external leadership to scale the business. Before Oura, Hale held senior roles at several consumer technology companies. He has overseen the company's expansion into AI-driven health coaching, its growing relationships with healthcare institutions, and the build-up to a public offering.

As a hired CEO rather than a founder, Hale's influence over the company's strategic direction is operational rather than governance-driven. The balance of voting power on the board is likely held by investors rather than concentrated in his hands.

Petteri Lahtela remains connected to the company in an undisclosed advisory or board capacity. Kari Kivelä and Markku Koskela are the technical co-founders who built the original hardware and firmware underlying the ring. Their current roles within the company are not publicly detailed.

The composition of Oura's board of directors has not been publicly disclosed in full. Given the investor lineup, it is reasonable to expect that representatives from The Chernin Group, Fidelity, and ICONIQ Capital hold board or observer seats, though this has not been confirmed.

Oura has navigated ongoing questions about whether its health tracking features constitute medical devices under FDA classification. The company has pursued FDA clearance for specific use cases, including heart rate monitoring and menstrual cycle tracking (marketed as Cycle Insights). Each cleared feature represents a regulatory milestone, but also a category of liability: cleared health claims create consumer expectations that require accuracy at scale.

As Oura adds more AI-driven health coaching features, the line between wellness product and medical device will draw greater regulatory attention, particularly from the FDA and its European equivalent, the CE mark framework.

Oura collects granular biometric data: resting heart rate, heart rate variability, skin temperature, blood oxygen levels, activity, and sleep architecture, continuously. This creates a sensitive data asset that is covered by multiple regulatory regimes: GDPR in Europe, HIPAA in healthcare contexts, and various US state privacy laws.

Any IPO filing will include mandatory disclosure of how Oura collects, stores, processes, and monetizes this data. The structure of its data practices will be scrutinized by investors, regulators, and privacy advocates.

Oura's ownership structure will directly shape the company's path through and beyond a public offering.

The presence of Dexcom as a strategic investor is the most consequential detail on the cap table. Dexcom connects Oura to the medical device ecosystem, opening potential partnerships in diabetes management and chronic disease monitoring. It also signals that Oura's long-term ambition extends beyond fitness tracking into clinical utility.

The gap between Oura's peak private valuation of $11 billion and the reported January 2026 tender offer discount suggests that market participants see some uncertainty about the IPO price. A public listing will resolve that ambiguity.

For users, the more pressing question is data. Who owns the health data that Oura's ring collects will become a central issue as the company transitions from private to public and expands its AI-driven features. The IPO prospectus will be the first full public accounting of those data practices.

Tom Hale is the CEO of Oura Health. He joined the company in 2022 to lead its commercial scaling phase. Before Oura, he held senior leadership roles at other consumer technology companies. He is not one of the original co-founders.

Not yet. Oura filed confidentially for a US IPO on May 21, 2026. The company's shares do not currently trade on any public exchange. IPO terms and a listing timeline have not been officially disclosed.

Oura was founded in 2013 by Petteri Lahtela, Kari Kivelä, and Markku Koskela in Oulu, Finland. Lahtela served as CEO until 2022, when Tom Hale was brought in to lead the company's next growth phase.

Exact ownership percentages are not publicly disclosed. The most prominent institutional investors are The Chernin Group, Forerunner Ventures, Fidelity Management and Research, ICONIQ Capital, and Dexcom. MSD Capital, Michael Dell's family office, is also a known backer. The three co-founders hold stakes of undisclosed size.

Oura has raised approximately $2.06 billion across 12 funding rounds, including a $900 million Series E in October 2025 and a separate $250 million revolving credit facility in September 2025.